NVO catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 9, 2026Sponsor estimate | NCT07769489Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and AcceptanceNovo Nordisk A/S · Healthy Participants | NVOLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Dec 13, 2026Sponsor estimate | NCT07225816Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in...Novo Nordisk A/S · Obesity | NVOLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Dec 31, 2026Sponsor estimate | NCT07656454A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in...Novo Nordisk A/S · Healthy Volunteers | NVOLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Dec 9, 2026Sponsor estimatePhase 1NCT07769489Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and AcceptanceNovo Nordisk A/S · Healthy ParticipantsRecruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 13, 2026Sponsor estimatePhase 1NCT07225816Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in...Novo Nordisk A/S · ObesityRecruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT07656454A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in...Novo Nordisk A/S · Healthy VolunteersRecruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 15, 2027Sponsor estimatePhase 1NCT07218627A Research Study on the Effects of NNC0537-1482 in Participants With Heart FailureNovo Nordisk A/S · Heart FailureRecruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2027Sponsor estimatePhase 1NCT06859073A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic HyperuricemiaNovo Nordisk A/S · Healthy VolunteersActive, not recruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 21, 2027Sponsor estimatePhase 1NCT07437079A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or ObesityNovo Nordisk A/S · OverweightRecruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2027Sponsor estimatePhase 1NCT07411560A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are...Novo Nordisk A/S · OverweightRecruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 1NCT07566390A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or ObesityNovo Nordisk A/S · ObesityRecruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 5, 2027Sponsor estimate | NCT07220564A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia ANovo Nordisk A/S · Haemophilia A | NVOLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 5, 2027Sponsor estimatePhase 1NCT07220564A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia ANovo Nordisk A/S · Haemophilia ARecruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.